Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ST-503 · 1 trial · 1 indication
To assess safety and tolerability of ST-503 over a 12-week post-dosing observation period.
| Arm | Type | Description |
|---|---|---|
| Sham Controlled Study | SHAM_COMPARATOR | - |
| Investigational Agent | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ST-503 | GENETIC | Genomic Medicine |
| Sham (No Treatment) | PROCEDURE | Sham Procedure |
Inclusion Criteria 1. Diagnostic characterization of Small Fiber Neuropathy (SFN) according to the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) criteria. 2. Medical record documentation that pain is refractory to 2 of 3 categori...
ST-503 is an investigational gene therapy being developed by Sangamo Therapeutics, Inc. for chronic neuropathic pain. It is designed to address refractory pain due to peripheral neuropathy, specifically the small fiber predominant form. ST-503 is currently in Phase 1 clinical development and has not been approved by any regulatory agency.
ST-503 targets Nav1.7, a voltage-gated sodium channel involved in pain signaling. By targeting Nav1.7 at the gene level, ST-503 aims to reduce pain associated with peripheral neuropathy. This gene therapy approach is intended to provide long-lasting pain relief by modifying the underlying mechanism of chronic neuropathic pain.
ST-503 is being developed by Sangamo Therapeutics, Inc., a biotechnology company focused on genomic medicines. Sangamo trades on the Nasdaq under the ticker symbol SGMO. The company is responsible for the clinical development of ST-503 for chronic neuropathic pain.
ST-503 is in Phase 1 clinical development. The ongoing trial is a safety and tolerability study in patients with refractory pain due to peripheral neuropathy. As a Phase 1 investigational therapy, ST-503 has not received FDA approval and remains in early-stage testing.
ST-503 is being evaluated in a single Phase 1 clinical trial, NCT06980948, titled "Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)." The trial is currently recruiting in the United States and plans to enroll 27 participants.
ST-503 is a distinct gene therapy candidate developed by Sangamo Therapeutics. It is not known by any alternative names. ST-503 specifically targets Nav1.7 for chronic neuropathic pain and is currently in Phase 1 testing.